- Home
- Our Company
- Our societal impact
- Global Health Equity
- Global health equity news & press releases
Global health equity news & press releases
The Global Health Equity Newsletter: Doubling down on health equity
The challenge to address health inequities
Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model
The antiviral JNJ-1802 induced prophylactic antiviral activity against dengue in a human challenge model Dengue infects millions of people annually and could impact many more as climate change fuels outbreaks The antiviral, previously found to be safe and well-tolerated, is now in a community-based field study to establish efficacy in a real-world setting
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatmentsi Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal of Medicine
5 things we now know about the tropical disease dengue
As global temperatures continue to rise, so too does the incidence of this mosquito-borne virus. For World Neglected Tropical Disease Day, learn the latest about this growing health threat and how Johnson & Johnson is working to combat it.
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
The new Satellite Center will work to accelerate discovery research against flaviviruses, including dengue, which impacts 400 million people each year This effort will build on Johnson & Johnson’s decade-long legacy and ongoing collaboration with Duke-NUS in early-stage dengue research The Satellite Center is the first Asia Pacific site in Johnson & Johnson’s network of research collaborations aimed at addressing entrenched and emerging pandemic threats
5 things to know about how Johnson & Johnson is helping kids with intestinal worms
For World Neglected Tropical Diseases Day, check out a video highlighting the company’s commitment to caring for children with these common infections across the globe.
Johnson & Johnson Marks More Than 2 Billion Doses of Medicine Donated to Date to Help Combat Intestinal Worms
Millions of children in more than 50 countries have received deworming medication since the donation program began in 2006, enabling them to grow and thrive The Company continues to build upon its longstanding commitment to address neglected tropical diseases through R&D efforts targeting dengue and leprosy
This ring may just help protect women against HIV
As the International AIDS Conference kicks off, learn how a new tool will help give this group greater power to prevent HIV on a monthly basis.
“I want to live a life that’s not defined by my schizophrenia”
For World Schizophrenia Day, learn about how one inspiring young man with the condition is thriving despite the challenges—and how Johnson & Johnson is helping him and others like him to find new ways to manage their mental illness.
How Johnson & Johnson is supporting the next great leaders in mental health
Meet four students dedicated to removing the stigma of mental illness and increasing access to crucial treatments around the world—with the help of the Global Mental Health Scholarship Fund.
“1.5 million children are living with HIV in sub-Saharan Africa. I’m one of the doctors treating these young patients every day”
A relaunched Johnson & Johnson partnership will help ensure that many young patients get lifesaving access to HIV medicines. Meet a doctor in Kenya who explains why the program is so crucial.
2 pandemics, 1 goal: Meet 4 innovators with high-tech ideas for fighting tuberculosis in the time of COVID-19
Despite being preventable and curable, tuberculosis is one of the world’s deadliest infectious diseases—and COVID-19 is making it even harder to diagnose and treat it. Enter these healthcare visionaries, who’ve made it their mission to move the world closer to the goal of ending tuberculosis.
3 ways Johnson & Johnson is innovating to help fight tuberculosis
It’s one of the world’s deadliest infectious diseases, killing more people each year than HIV/AIDS and malaria combined. We’re taking a look back at the strides the company has made in fighting this preventable illness to help bring us closer to a tuberculosis-free world.
At the heart of science: How a small chewable tablet is helping tackle a disease that impacts nearly 1 billion children globally
Imagine getting so sick from a preventable disease that you can’t play or attend school—multiple times a year. For World Children’s Day, we’re sharing the story of Sheti and others just like her who now have a chance to take back their childhoods, thanks to a new formulation of a medication to treat intestinal worms.
6 latest facts about Johnson & Johnson’s Ebola vaccine
In response to a new Ebola outbreak in Guinea, Johnson & Johnson is providing up to 200,000 doses of its Ebola vaccine regimen to the country for a World Health Organization supported clinical trial. Learn more about the initiative and other top facts about the vaccine regimen for the deadly virus.
“I’m a scientist working on a potential COVID-19 vaccine”: Meet a researcher who’s studying a promising candidate
Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
“I have never seen a moment so rich in collaboration, ingenuity and acts of bravery": Johnson & Johnson announces it has identified a lead COVID-19 vaccine candidate
Chairman & CEO Alex Gorsky shares that the company could have the first batches of a COVID-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.